



(11) **EP 2 747 767 B8**

(12) **CORRECTED EUROPEAN PATENT SPECIFICATION**

(15) Correction information:
Corrected version no 1 (W1 B1)
Corrections, see
Bibliography INID code(s) 73

(51) Int Cl.:
A61K 31/497 ^(2006.01) **C07D 401/04** ^(2006.01)
C07D 403/04 ^(2006.01) **C07D 413/04** ^(2006.01)
C07D 241/42 ^(2006.01) **C07D 241/44** ^(2006.01)
A61P 35/00 ^(2006.01)

(48) Corrigendum issued on:
17.07.2019 Bulletin 2019/29

(86) International application number:
PCT/US2012/052390

(45) Date of publication and mention
of the grant of the patent:
20.02.2019 Bulletin 2019/08

(87) International publication number:
WO 2013/032951 (07.03.2013 Gazette 2013/10)

(21) Application number: **12828679.6**

(22) Date of filing: **24.08.2012**

(54) **CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS**

BESTIMMTE CHEMISCHE STOFFE, ZUSAMMENSETZUNGEN UND VERFAHREN
ENTITÉS CHIMIQUES, COMPOSITIONS ET PROCÉDÉS

(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB
GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO
PL PT RO RS SE SI SK SM TR

(74) Representative: **Mewburn Ellis LLP**
City Tower
40 Basinghall Street
London EC2V 5DE (GB)

(30) Priority: **26.08.2011 US 201161528033 P**
27.08.2011 US 201161528151 P

(56) References cited:
WO-A1-2005/037285 WO-A1-2009/012283
WO-A2-2007/044729 US-A1- 2010 286 142

(43) Date of publication of application:
02.07.2014 Bulletin 2014/27

(73) Proprietor: **Neupharma, Inc.**
Foster City, CA 94404 (US)

- **TSAI ET AL.:** 'Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity.' **PNAS vol. 105, no. 8, 2008, pages 3041 - 3046, XP008146063**
- **BOLLAG ET AL.:** 'Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma.' **NATURE vol. 467, no. 7315, 2010, pages 596 - 599, XP055145926**

(72) Inventors:

- **ZHU, Yong-liang**
Fremont, CA 94539 (US)
- **QIAN, Xiangping**
Foster City, CA 94404 (US)

Remarks:

The file contains technical information submitted after the application was filed and not included in this specification

EP 2 747 767 B8

Note: Within nine months of the publication of the mention of the grant of the European patent in the European Patent Bulletin, any person may give notice to the European Patent Office of opposition to that patent, in accordance with the Implementing Regulations. Notice of opposition shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).